Pepscope Joins GLIOTRAIN Consortium

Updated: Jan 5, 2019



Worldwide, an estimated 240,000 cases of brain and nervous system tumors are diagnosed every year, and Glioblastoma Multiforme (glioma, GBM) is the most frequent and aggressive brain tumor. New treatment options, and effective precision medicine therapies are urgently required. GLIOTRAIN is a multi-sectoral industry-academia collaboration, funded by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie ITN initiative, that will work to identify novel strategies to treat GBM as well as investigating resistance mechanisms in this devastating disease. Pepscope will be involved in phosphoproteomic profiling of 3D glioma models with the aim to elucidate mechanisms of therapy resistance.


GLIOTRAIN has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 766069.